What Fonturacetam Treats: Main Uses and Benefits

The therapeutic focus of Fonturacetam (Phenylpiracetam) generally lies in addressing symptom clusters that interfere with daily functioning, specifically those related to cognitive deficits and physical strain following neurological stress. This compound is used within therapeutic areas involving certain distressing symptoms, such as mental function disorders and cerebrovascular impairment.

The medication is commonly applied in clinical settings for conditions marked by heightened symptom clusters of co-occurring cognitive decline and fatigue. Indications relevant to its use include asthenia, deficits in memory and attention, and sequelae following traumatic brain injury or complications of cerebrovascular deficiency.

---

Supporting Management and Benefit

The medication provides supportive symptomatic assistance, which may help patients cope more steadily during difficult episodes. “It is commonly used to address the chronic or reactive fatigue that interferes with daily stability.” By easing the symptom burden of profound mental and physical fatigue, the medication may assist with maintaining functional stability and supports general well-being during symptomatic phases. The compound is considered relevant for instances where short-term symptomatic assistance is needed to manage symptoms that interfere with daily comfort.

Quick Fact	Symptom Relief Focus
Symptom Management for Fatigue	Asthenia (profound exhaustion) and physiological strain.
Symptom Management for Cognition	Deficits in concentrated attention and memory function.

Regulatory References

1. New Zealand Medicines and Medical Devices Safety Authority

The official eligibility profile for Fonturacetam (Phenylpiracetam) is defined by its regulatory status: it is an unapproved drug for medical use in many Western countries, while regulated as prescription-only in authorized regions. The medicine is permitted for use in the adult population (18 years and older) in countries where it is formally authorized.

---

Category	Official Eligibility Status
Populations for whom use is contraindicated	Individuals with known hypersensitivity to the drug or excipients. Patients with severe renal impairment, severe hypertension, severe atherosclerosis, or severe psychiatric disorders (including acute psychotic states). Women who are pregnant or breastfeeding (lactation).
Age-related eligibility rules	Contraindicated or use not established in children and adolescents under 18 years of age.
Eligibility-related restrictions	Use with caution is formally required in the older adult population and in patients with mild to moderate hepatic or renal impairment.

---

The regulatory framework defines eligibility through non-negotiable prohibitions tied to specific physiological and pre-existing conditions, which are documented in the official prescribing information.

Interactions with other medicines and products

Fonturacetam (Phenylpiracetam) is not approved or regulated by the U.S. Food and Drug Administration (FDA) or the European Medicines Agency (EMA). Consequently, there is no standardized Summary of Product Characteristics (SmPC) or official prescribing information from these authorities detailing its drug-drug interaction profile. The official regulatory record, as documented by major Western authorities, is characterized by the absence of specific, citable entries for major interaction categories.

Regarding pharmacokinetic interactions, there are no official statements detailing whether Fonturacetam acts as an inhibitor or inducer of major cytochrome P450 (CYP) enzymes, nor are there documented interactions related to drug transport systems such as P-glycoprotein (P-gp). The documentation does not formally classify any contraindicated combinations, meaning no medicinal product or product class is explicitly prohibited for co-administration based on interaction risk. Furthermore, the official regulatory sources do not cite specific pharmacodynamic concerns, such as warnings for additive effects with other central nervous system agents. There are no mandatory administration timing rules requiring separation from food, alcohol, or other medicines detailed in the official government records.

Modulation of Catecholaminergic and Excitatory Systems

The mechanism of Fonturacetam involves dual-system modulation within the central nervous system (CNS). The primary action centers on the Central Catecholaminergic System, specifically as a selective reuptake inhibitor of the Dopamine Transporter (DAT). This molecular blockade prevents the rapid reabsorption of the neurotransmitter dopamine from the synapse, leading to an elevated and sustained concentration of extracellular dopamine. Fonturacetam also acts as a weaker inhibitor of the Norepinephrine Transporter (NET). The DAT inhibition directly modulates neural circuits responsible for psychomotor activity and effort regulation, which contributes to the modulation of pathways involved in sustained psychomotor effort.

The secondary mechanism involves the glutamatergic pathway. Fonturacetam functions as a positive allosteric modulator of AMPA receptors, enhancing their responsiveness to the neurotransmitter glutamate. This action supports the physiological processes of synaptic plasticity and influences circuits involved in attentional filtering.

Structurally, Fonturacetam is a racemate; its ( R)-enantiomer drives the principal mechanism of psychomotor activation due to its greater affinity for the DAT. The overall effect is the modulation of key systems governing drive and cognitive efficiency.

How Fonturacetam is Used: Administration Guidelines

Fonturacetam (Phenylpiracetam) is an oral medication with specific use instructions. These guidelines define the administration route, standard dosages, and the typical duration of a treatment course.

Administration and Dosage

The medicine is administered orally and is available in tablet form, typically at a strength of 100 mg.

Administration Property	Standard Instruction
Route of Administration	Oral (Taken by mouth as a tablet)
Standard Daily Dose	Generally 100 mg to 200 mg per day
Maximum Daily Dose	Up to 300 mg per day for certain specific conditions
Dosing Frequency	Once or Twice daily
Time of Day	Administration is often recommended to be completed before 3:00 PM (15:00) to minimize potential sleep interference.

The dosing parameters are based on standardized medical use protocols and descriptive reports detailing the application of the substance.

Treatment Duration and Specific Instructions

Fonturacetam is intended for use in defined, time-limited courses, not for continuous long-term therapy.

• Typical Course Length: The average recommended course of treatment is 30 days (one month).
• Special Populations: Prescribing information does not generally specify quantified dosage adjustments for older adults or those with renal or hepatic impairment, relying on the standard adult dose range.
• Administration Context: The tablets are administered intact, and no special preparation or dilution is required. Instructions do not mandate taking the dose with or without food.

This structured approach ensures the medicine is used within established limits and protocols.

Research evidence / Overview of studies for Fonturacetam

Research Studies Examining Asthenia (Profound Mental and Physical Fatigue)

Research has explored Fonturacetam in conditions where patients experience significant mental and physical fatigue, known as asthenia. The evidence base includes systematic reviews, meta-analyses of clinical trials, and several short-term Randomized Controlled Trials (RCTs). These studies were applied in research contexts involving fluctuating symptoms in adult populations, including those with chronic neurological issues.

Investigators monitored outcomes related to systemic or functional imbalance by measuring the severity of fatigue, often using standardized instruments. Findings describe patterns observed in the studies where measurements of fatigue and quality of life showed changes over the typical treatment course of approximately 30 days.

Research Studies Examining Neurological and Cognitive Outcomes

Fonturacetam was studied for research on symptom patterns following certain cerebrovascular events, such as ischemic stroke, and in individuals with chronic brain circulation issues. This research examined temporary physiological imbalance through randomized controlled studies, monitoring outcomes reflecting functional status and activities of daily living in adult populations.

Research on deficits in memory and concentrated attention was primarily conducted using secondary outcome measurements within these larger trials. Investigators monitored metrics related to attention, verbal memory, and speed of cognitive operations, reporting patterns that were observed alongside the primary outcomes for fatigue.

Long-Term Data and Research Uncertainty

The available research base provides context on symptom patterns over short-term intervals. Clinical trials primarily describe changes over a typical 30-day course, and while some observations extend up to a year, research suggests certainty remains low regarding the persistence of observed patterns over several years. Evidence is limited for certain subgroups, meaning results apply only to the specific adult populations studied.

Furthermore, comparative evidence is lacking for certain indications, and long-term effects on functional stability and symptom recurrence are not fully established in the current body of research.

Key Studies & References

1. Minutes of the Medicines Classification Committee: Racetams (Medsafe, New Zealand)
2. World Health Organization Collaborating Centre for Drug Statistics Methodology (WHO-DD): ATC/DDD Index

Common questions about Fonturacetam (FAQ)

Q: How is Fonturacetam different from other '-racetam' medicines?

A: Fonturacetam is structurally related to its predecessor, Piracetam, but includes a specific phenyl group in its structure. This modification is described in pharmacological studies as reported to influence the compound's properties and ability to penetrate the blood-brain barrier.

Q: Why do some people refer to Fonturacetam by another name?

A: The substance is formally recognized by the International Nonproprietary Name (INN) Fonturacetam, and also by its chemical synonym Phenylpiracetam. In regions where it is formally authorized, the medicine is available under various trade names, such as Phenotropil.

Q: Are there any known common side effects of Fonturacetam?

A: Official regulatory documents list documented adverse reactions such as insomnia or sleep disturbances, psychomotor agitation (restlessness), increased blood pressure, flushing, and hypersensitivity. It is important to note that the precise frequency (e.g., 'common' or 'rare') of these reactions is officially listed as undetermined.

Q: Why is Fonturacetam sometimes discussed in academic research?

A: Studies and official information indicate that the drug is studied in research contexts because of its unique classification as a phenylated racetam. It is of interest due to its mechanism involving the dual modulation of the central nervous system, particularly as an atypical dopamine reuptake inhibitor.

Q: What common medicines are listed in official documents as potentially interacting with Fonturacetam?

A: Official safety documentation advises caution regarding use with central nervous system (CNS) stimulants and other psychoactive medications. This is due to the potential for Fonturacetam to potentiate, or amplify, the effects of these agents.

Q: What should be done about possible allergic reactions to Fonturacetam?

A: Regulatory documents cite known hypersensitivity to the substance as a specific contraindication for use. If symptoms suggesting an allergic reaction, such as a rash or swelling, are observed, seeking immediate emergency medical assistance is advised.

Q: Why is the availability of Fonturacetam different in various countries?

A: The drug’s regulatory status varies significantly by location. It is approved and regulated as a prescription-only medicine in authorized regions, such as parts of Eastern Europe and Australia. Conversely, it is classified as an unapproved drug for medical use by major authorities in many Western countries, including the US FDA and the EMA.

Q: Does Fonturacetam have different brand names internationally?

A: Yes. In regions where it is formally authorized for medical use, Fonturacetam is available under various trade names, including Phenotropil, Actitropil, and others.

Q: Do studies suggest Fonturacetam is associated with changes in mood?

A: Official safety information lists psychomotor agitation, or restlessness, as a documented adverse reaction. This is an effect that involves an individual's psychological state and suggests a potential for changes in mental or emotional status.

Q: How does Fonturacetam compare to piracetam in its intended purpose?

A: Official regulatory documents do not contain direct comparisons of the two substances. However, like its structural relative Piracetam, Fonturacetam has been studied for a range of purposes including its antiasthenic (anti-fatigue) and cognitive effects.

Q: What are the official regulatory statements regarding the research on Fonturacetam?

A: Official summaries characterize the evidence by noting specific limitations in the current research base. These include low certainty regarding the persistence of observed patterns over several years, limited evidence available for certain subgroups, and a lack of comparative evidence for some indications.

Q: Can Fonturacetam be crushed or split?

A: Official administration instructions specify that the tablets must be administered intact. The product label does not contain instructions that would allow for the tablet to be crushed, split, or modified before being taken.

Q: Is Fonturacetam considered a controlled substance?

A: In the United States, Fonturacetam is not scheduled as a controlled substance by the Drug Enforcement Administration (DEA). However, in countries where it is formally authorized, such as Australia and Russia, it is regulated strictly as a prescription-only medicine.

Q: What is the time frame for when Fonturacetam starts working?

A: According to pharmacokinetic data, the drug is described as having a rapid uptake into the body. Official summaries indicate that the onset of action is typically observed in less than one hour after administration.

Q: Does Fonturacetam build up in the body over time?

A: The drug is characterized by its rapid elimination half-life, which is approximately 3 to 5 hours. This means the substance is quickly cleared from the body and does not accumulate significantly over the course of the time-limited treatment period.

Q: If a person forgets to take a scheduled dose, what is the general guidance (non-directive)?

A: General guidance for prescription medicines taken once or twice daily advises taking the missed dose as soon as it is remembered, unless the next dose is due shortly. General protocol also advises against taking a double dose to make up for a forgotten dose.

Q: Does official documentation mention any warnings about driving or operating machinery while using Fonturacetam?

A: Official safety information notes stimulant-related adverse reactions, such as psychomotor agitation. Warnings regarding tasks requiring focused attention or physical coordination are often given for medicines that have known effects on the central nervous system.

Q: How long does the general effect of Fonturacetam typically last?

A: The duration of the drug’s general effect is associated with its elimination half-life. Official pharmacokinetic summaries indicate this half-life is approximately 3 to 5 hours.

Q: What happens if someone takes too much Fonturacetam (non-directive, non-advice)?

A: Specific protocols for an overdose are not widely published in regulatory summaries. In any case where an amount exceeding the maximum daily dose is taken, general medical guidance recommends that immediate emergency medical assistance be sought.

Q: How is Fonturacetam eliminated from the body?

A: According to pharmacokinetic data from official summaries, the drug is primarily eliminated from the body through the kidneys. The main route of excretion is via the urine.

Storage and Handling Requirements

Fonturacetam must be stored under conditions that maintain its stability, as mandated by general pharmaceutical standards. The product should be kept at controlled room temperature (e.g., 20 C to 25 C), protected from freezing and excessive heat.

To preserve product integrity, the container must be kept tightly closed in a dry place, away from moisture and light. All medicines, including this product, must be stored out of the sight and reach of children and pets, with official regulatory guidance requiring it to be stored locked up.

Disposal Instructions

Disposal of unused or expired product must be executed in accordance with local, regional, and national regulations. The preferred methods for disposal, recommended by national health authorities, include utilizing drug take-back locations or prepaid mail-back programs when available in the community.